PRMA Insights: The Roadmap to Pricing and Reimbursement Success

The metastatic breast cancer report delivers

Use this report to gain an understanding of the following issues in the pricing and reimbursement of metastatic breast cancer in the major markets:

• An overview of metastatic breast cancer with a focus on the key issues shaping the market access landscape.
  
• A comprehensive review of metastatic breast cancer products, regulatory indications, key supporting data packages and the position in clinical guidelines.
  
• How payers have critically evaluated the data packages for existing metastatic breast cancer products including chemotherapies, targeted therapies and aromatase inhibitors.
  
• An in-depth critical review of over 30 pricing and reimbursement and HTA assessments in metastatic breast cancer in the major markets.
  
• The price existing products have achieved and their reimbursement status in each country.
  
• The value propositions and arguments manufacturers have submitted for their products.
  
• A review of the relevant risk sharing agreements for products indicated for metastatic breast cancer.
  
• The implications surrounding the choice of comparators and endpoints included in the clinical trials in pricing and reimbursement.
  
• The key learnings and market access insights for developing a new product in metastatic breast cancer.
  
• A review of the epidemiology and burden of metastatic breast cancer with insights into evidence gaps and the impact on your health outcomes strategy.
  
• A review of the existing instruments used to measure Health Related Quality of Life (HRQoL) in metastatic breast cancer, opportunities for the inclusion of HRQoL data in your label and how this could differentiate your product and impact pricing and reimbursement. 
  
  

Find out more about the metastatic breast cancer report:

The report delivers         Scope of the report        Authors of the report